Kryptoscan (Krypton (81mkr))

Krypton is a noble gas; when inhaled it does not undergo metabolic conversion. Its primary action is physical—providing a stable, inert gas that can be detected by imaging equipment or used to study respiratory physiology. Any physiological impact is due to its physical properties rather than binding to receptors.

The dosage of Kryptoscan is determined by the prescribing investigator or clinician based on the specific protocol, equipment, and study requirements. No standard dose is established; the prescriber sets the volume and concentration appropriate for the intended use.

Safety data for Kryptoscan in pregnant or lactating individuals are limited. Because the product is intended for research use only, it should be avoided in these populations unless a risk‑benefit assessment by a qualified professional justifies its use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other inert gases such as xenon or argon, Krypton offers a distinct atomic weight and radiographic signature, which may be advantageous for certain imaging modalities. However, its availability, cost, and specific physical properties differ, and the choice of gas depends on the study’s technical requirements and regulatory considerations.

Kryptoscan should be stored at ambient temperature, below 25 °C, in its original sealed container, protected from moisture and direct sunlight. Handling requires use of appropriate gas cylinders, ventilation, and adherence to safety protocols to prevent accidental inhalation or release.

Kryptoscan is delivered via a calibrated inhalation system or gas cylinder, allowing the prescriber to control the concentration and flow rate. Administration is performed by trained personnel in a controlled environment, ensuring the patient inhales the prescribed amount under monitoring.

Although Krypton is chemically inert, serious risks may include respiratory irritation, hypoxia if administered in excessive concentrations, or accidental over‑exposure leading to dizziness or loss of consciousness. Immediate medical evaluation is required if severe symptoms occur.

Individuals with known hypersensitivity to inert gases, severe respiratory disorders, or those for whom inhalation of any gas could compromise oxygenation should avoid Kryptoscan. Additionally, it is contraindicated for pregnant or breastfeeding persons unless a specialist determines that benefits outweigh potential risks.